Lack of clinically significant pharmacological interactions between ticagrelor and enoxaparin or unfractionated heparin in healthy subjects.

Journal of clinical pharmacy and therapeutics 20121201

The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day.

Drugs 20121112

Safety profile and bleeding risk of ticagrelor compared with clopidogrel.

Expert opinion on drug safety 20121101

[Platelet inhibitors in clinical practice].

Therapeutische Umschau. Revue therapeutique 20121101

Identification of high-affinity P2Y₁₂ antagonists based on a phenylpyrazole glutamic acid piperazine backbone.

Journal of medicinal chemistry 20121025

Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery.

Journal of the American College of Cardiology 20121023

Antiplatelet therapy for patients with diabetes mellitus and acute coronary syndrome.

Primary care diabetes 20121001

Current antiplatelet options for NSTE-ACS patients.

QJM : monthly journal of the Association of Physicians 20121001

Improving long-term ACS management: is there a role for the new antiplatelets?

Journal of interventional cardiology 20121001

Acute ST-elevation myocardial infarction.

Current opinion in critical care 20121001

Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model.

Thrombosis research 20121001

Review of ticagrelor in the management of acute coronary syndromes.

Expert opinion on drug metabolism & toxicology 20121001

New anti-platelet agents: the end of resistance?

Thrombosis research 20121001

Ticagrelor (brilinta), an antiplatelet drug for acute coronary syndrome.

P & T : a peer-reviewed journal for formulary management 20121001

Letter by Fort and Plachetka regarding article, 'association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from PLATO'.

Circulation 20120911

Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with severe renal impairment.

Journal of clinical pharmacology 20120901

Platelets in atherothrombosis--diagnostic and prognostic value of platelet activation in patients with atherosclerotic diseases.

Current vascular pharmacology 20120901

Platelet hyperreactivity and stent thrombosis in patients undergoing coronary stenting.

Current vascular pharmacology 20120901

P2Y(12) receptors in platelets and other hematopoietic and non-hematopoietic cells.

Purinergic signalling 20120901

Novel antiplatelet therapy in acute coronary syndromes: what is new in the pipeline?

Current vascular pharmacology 20120901

Antiplatelet therapy: Treatment with ticagrelor for 12 months after ACS is cost-effective.

Nature reviews. Cardiology 20120901

Updating an institutional chest pain algorithm: incorporating new evidence on emerging pharmacotherapy.

Critical pathways in cardiology 20120901

Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials--common patterns in TRITON, RECORD, and PLATO?

Thrombosis and haemostasis 20120901

UA/NSTEMI: Are you following the latest guidelines?

Nursing 20120901

Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.

American heart journal 20120901

Ticagrelor: molecular discovery to clinical evidence: ticagrelor: a novel antiplatelet agent.

Indian heart journal 20120901

[Medication of the month. Ticagrelor (Brilique): potent oral antagonist of platelet activity].

Revue medicale de Liege 20120901

Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome.

Cardiovascular therapeutics 20120801

Lack of significant food effect on the pharmacokinetics of ticagrelor in healthy volunteers.

Journal of clinical pharmacy and therapeutics 20120801

Effect of age and gender on pharmacokinetics and pharmacodynamics of a single ticagrelor dose in healthy individuals.

European journal of clinical pharmacology 20120801

Which antiplatelet agent for whom? Which patient populations benefit most from novel antiplatelet agents (ticagrelor, prasugrel)?

Current cardiology reports 20120801

Platelet function and inhibition in ischemic heart disease.

Current cardiology reports 20120801

Network meta-analysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions.

Thrombosis and haemostasis 20120801

Ticagrelor in clopidogrel-resistant patients undergoing maintenance hemodialysis.

American journal of kidney diseases : the official journal of the National Kidney Foundation 20120801

Clinical pharmacogenomics of warfarin and clopidogrel.

Journal of pharmacy practice 20120801

Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.

Journal of the American College of Cardiology 20120717

Quantitative comparison of clopidogrel 600 mg, prasugrel and ticagrelor, against clopidogrel 300 mg on major adverse cardiovascular events and bleeding in coronary stenting: synthesis of CURRENT-OASIS-7, TRITON-TIMI-38 and PLATO.

International journal of cardiology 20120712

Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial.

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20120710

Ticagrelor, but not clopidogrel and prasugrel, prevents ADP-induced vascular smooth muscle cell contraction: a placebo-controlled study in rats.

Thrombosis research 20120701

Prasugrel during primary percutaneous coronary intervention: evidence from clinical data.

Current vascular pharmacology 20120701

Ticagrelor in ST-elevation myocardial infarction.

Current vascular pharmacology 20120701

Advances in antiplatelet therapy for acute coronary syndromes.

Postgraduate medical journal 20120701

Lessons from platelet inhibition and patient outcomes.

Current opinion in cardiology 20120701

Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications.

Clinical pharmacokinetics 20120701

Farnesyl pyrophosphate is an endogenous antagonist to ADP-stimulated P2Y₁₂ receptor-mediated platelet aggregation.

Thrombosis and haemostasis 20120701

New drugs 2012, part 2.

Nursing 20120701

Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies.

American heart journal 20120701

Atopaxar: a review of its mechanism of action and role in patients with coronary artery disease.

Future cardiology 20120701

Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack.

Circulation 20120612

Beware of novel antiplatelet therapy in acute coronary syndrome patients with previous stroke.

Circulation 20120612

Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model.

Journal of cardiovascular pharmacology and therapeutics 20120601

Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies.

Clinical pharmacokinetics 20120601

Ticagrelor: oral reversible P2Y(12) receptor antagonist for the management of acute coronary syndromes.

Clinical therapeutics 20120601

Synthesis and biological evaluation of ticagrelor derivatives as novel antiplatelet agents.

Bioorganic & medicinal chemistry letters 20120601

Management of non-ST-segment elevation acute coronary syndrome: comparison of the updated guidelines from North America and Europe.

Critical pathways in cardiology 20120601

Use of cilostazol in percutaneous coronary interventions.

The Annals of pharmacotherapy 20120601

Meeting new challenges with antiplatelet therapy in primary care.

The Journal of family practice 20120601

[Platelet function: new drugs, new assays : possible impacts on operative medicine?].

Der Anaesthesist 20120601

Unstable angina and non-ST elevation myocardial infarction.

American journal of respiratory and critical care medicine 20120501

Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor.

Clinical pharmacokinetics 20120501

Personalised antiplatelet therapy in stent thrombosis: observations from the Clopidogrel Resistance in Stent Thrombosis (CREST) registry.

Heart (British Cardiac Society) 20120501

Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes.

Expert review of clinical pharmacology 20120501

Mechanisms of Platelet Activation and Integrin αIIβ3.

Korean circulation journal 20120501

Cardiac dysfunction in the CABG patient.

Current opinion in pharmacology 20120401

[Modern treatment in acute coronary syndrome].

Deutsche medizinische Wochenschrift (1946) 20120401

Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.

Hospital practice (1995) 20120401

Ticagrelor: a new option for ACS.

The Nurse practitioner 20120313

Antiplatelet therapy: controversial aspects.

Thrombosis research 20120301

[New antiplatelet agents and the question of dual antiplatelet therapy].

Der Internist 20120301

Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 20120301

Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome.

Pharmacotherapy 20120301

Peripheral vascular outcomes in the PLATO trial: update from the FDA ticagrelor complete response review.

American journal of therapeutics 20120301

Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial.

Circulation 20120227

Ticagrelor induces adenosine triphosphate release from human red blood cells.

Biochemical and biophysical research communications 20120224

Optimizing antiplatelet therapy in acute coronary syndrome and percutaneous coronary intervention.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20120201

Antiplatelet and anticoagulant drugs in interventional radiology.

Cardiovascular and interventional radiology 20120201

Antiplatelet function variability in clopidogrel-treated patients: need for new antiplatelet agents.

Fundamental & clinical pharmacology 20120201

Clinical effects and outcomes with new P2Y12 inhibitors in ACS.

Fundamental & clinical pharmacology 20120201

In pursuit of P2X3 antagonists: novel therapeutics for chronic pain and afferent sensitization.

Purinergic signalling 20120201

Novel antiplatelet therapies.

Current atherosclerosis reports 20120201

Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study.

Clinical drug investigation 20120201

Antiplatelet therapy in patients with ST-elevation myocardial infarction undergoing myocardial revascularisation: beyond clopidogrel.

Current medical research and opinion 20120201

P2Y12 platelet inhibition in clinical practice.

Journal of thrombosis and thrombolysis 20120201

Optimal management of antiplatelet therapy and proton pump inhibition following percutaneous coronary intervention.

Current treatment options in cardiovascular medicine 20120201

Management of coagulation: an Australian perspective.

Current opinion in anaesthesiology 20120201

Evaluation and characterization of the effects of ticagrelor on serum and urinary uric acid in healthy volunteers.

Clinical pharmacology and therapeutics 20120201

A comprehensive comparative review of adenosine diphosphate receptor antagonists.

Expert opinion on pharmacotherapy 20120201

InforMatrix: ADP antagonists in acute coronary syndromes.

Expert opinion on pharmacotherapy 20120201

Effect size of ticagrelor over clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial: from statistics to clinical judgment.

Journal of cardiovascular medicine (Hagerstown, Md.) 20120201

'Conversations in cardiology': How do you pick the best antiplatelet drug--clopidogrel, prasugrel, ticagrelor for your PCI patient?

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 20120201

Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Chest 20120201

ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy.

Circulation 20120124

No one-size-fits-all: A tailored approach to antithrombotic therapy after stent implantation.

Circulation 20120124

Do aspirin and other antiplatelet drugs reduce the mortality in critically ill patients?

Thrombosis 20120101

Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study.

Clinical chemistry 20120101

Antiplatelet therapy in acute coronary syndromes.

Expert opinion on pharmacotherapy 20120101

Recent advances in epidural analgesia.

Anesthesiology research and practice 20120101

Bleeding tendency in dual antiplatelet therapy with aspirin/clopidogrel: rescue of the template bleeding time in a single-center prospective study.

Thrombosis journal 20120101

Antiplatelet therapy in atherothrombotic cardiovascular diseases for primary and secondary prevention: a focus on old and new antiplatelet agents.

Current pharmaceutical design 20120101

Trends in qualifying biomarkers in drug safety. Consensus of the 2011 meeting of the spanish society of clinical pharmacology.

Frontiers in pharmacology 20120101

New perspectives in antiplatelet therapy.

Current medicinal chemistry 20120101

Increased atherothrombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapy.

Cardiology research and practice 20120101

A critical appraisal of the functional evolution of P2Y12 antagonists as antiplatelet drugs.

Current pharmaceutical design 20120101

Evolving role of platelet function testing in coronary artery interventions.

Vascular health and risk management 20120101

Who protects physicians and patients from guidelines?

Cardiology 20120101

Serotonin antagonism improves platelet inhibition in clopidogrel low-responders after coronary stent placement: an in vitro pilot study.

PloS one 20120101

Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options.

Vascular health and risk management 20120101

[Optimal antiplatelet and antithrombotic therapy in patients with ST elevation myocardial infarction].

Kardiologia polska 20120101

[Letter to Kardiologia Polska concerning optimal treatment of myocardial infarction].

Kardiologia polska 20120101

The avantgarde carbostent in patients scheduled for undelayable noncardiac surgery.

Thrombosis 20120101

Chinese herb and formulas for promoting blood circulation and removing blood stasis and antiplatelet therapies.

Evidence-based complementary and alternative medicine : eCAM 20120101

The 'Harmonizing Optimal Strategy for Treatment of coronary artery stenosis - sAfety & effectiveneSS of drug-elUting stents & antiplatelet REgimen' (HOST-ASSURE) trial: study protocol for a randomized controlled trial.

Trials 20120101

Platelet adenosine diphosphate receptor antagonists: ticlopidine to ticagrelor-a long continuing journey.

Indian heart journal 20120101

Anticoagulant and antiplatelet therapy in patients with atrial fibrillation and coronary artery disease.

Thrombosis 20120101

Stent thrombosis: incidence, predictors and new technologies.

Thrombosis 20120101

Do Clopidogrel Nonresponders Have an Increased Risk of Adverse Events during Supra-Aortal Angioplasty and Stenting?

Stroke research and treatment 20120101

[New antithrombotic drugs].

Duodecim; laaketieteellinen aikakauskirja 20120101

Dabigatran for stroke prevention in nonvalvular atrial fibrillation: answers to challenging 'real-world' questions.

Thrombosis 20120101

Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor.

Platelets 20120101

Antiplatelet therapy - ticagrelor.

Hamostaseologie 20120101

Ticagrelor FDA approval issues revisited.

Cardiology 20120101

[The role of direct-acting P2Y12 inhibitors in acute coronary syndrome].

Kardiologiia 20120101

Impact of antiplatelet therapy in heart disease.

Advances in cardiology 20120101

Clopidogrel in coronary artery disease: update 2012.

Advances in cardiology 20120101

Antiplatelet therapy in acute coronary syndromes: ticagrelor.

Advances in cardiology 20120101

Genetic considerations.

Advances in cardiology 20120101

Advances in the monitoring of anti-P2Y12 therapy.

Platelets 20120101

Thienopyridines and other ADP-receptor antagonists.

Handbook of experimental pharmacology 20120101

Intracellular signaling as a potential target for antiplatelet therapy.

Handbook of experimental pharmacology 20120101

Antiplatelet therapy in peripheral artery disease.

Handbook of experimental pharmacology 20120101

Antiplatelet agents and anticoagulants for hypertension.

The Cochrane database of systematic reviews 20111207

Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes.

European heart journal 20111201

Clopidogrel resistance: identifying and overcoming a barrier to effective antiplatelet treatment.

Cardiovascular therapeutics 20111201

Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy).

The American journal of cardiology 20111201

Role of newly formed platelets in thrombus formation in rat after clopidogrel treatment: comparison to the reversible binding P2Y₁₂ antagonist ticagrelor.

Thrombosis and haemostasis 20111201

Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial.

European heart journal 20111201

No free lunches: balancing bleeding and efficacy with ticagrelor.

European heart journal 20111201

Unravelling the benefit against the risk of long-term dual antiplatelet therapy.

Current opinion in cardiology 20111201

[Who protects physicians and patients from guidelines?].

Deutsche medizinische Wochenschrift (1946) 20111201

Recent advances in the management of acute myocardial infarction.

The Journal of the Association of Physicians of India 20111201

Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease.

Journal of the American College of Cardiology 20111122

Genetic determinants of platelet response to clopidogrel.

Journal of thrombosis and thrombolysis 20111101

Role of platelet function testing in clinical practice: current concepts and future perspectives.

Current drug targets 20111101

Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.

Annals of medicine 20111101

Current concepts on coronary revascularization in diabetic patients.

European heart journal 20111101

Treating acute coronary syndromes with new antiplatelet drugs: the mortality issue with prasugrel and ticagrelor.

Current medical research and opinion 20111101

Female platelets are hard to control.

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 20111101

Antiplatelet options for secondary prevention in acute coronary syndromes.

Expert review of cardiovascular therapy 20111101

Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes.

Postgraduate medicine 20111101

[New era in antiplatelet therapy based on results from recent clinical trials].

Medicina clinica 20111022

Oral antiplatelet agents in ACS: from pharmacology to clinical differences.

Fundamental & clinical pharmacology 20111001

Anti-platelet therapy: ADP receptor antagonists.

British journal of clinical pharmacology 20111001

Genotypic and phenotypic assessment of platelet function and response to P2Y12 antagonists.

Current cardiology reports 20111001

Antiplatelet effects of aspirin vary with level of P2Y₁₂ receptor blockade supplied by either ticagrelor or prasugrel.

Journal of thrombosis and haemostasis : JTH 20111001

Vorapaxar: a novel protease-activated receptor-1 inhibitor.

Expert opinion on investigational drugs 20111001

Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction--a hospital registry-primary care linked cohort (MINAP-GPRD).

European heart journal 20111001

Use of prasugrel in a patient with clopidogrel hypersensitivity.

The Annals of pharmacotherapy 20111001

Variability of clopidogrel response in patients with type 2 diabetes mellitus.

Diabetes & vascular disease research 20111001

Ticagrelor. Acute coronary syndromes: nothing new.

Prescrire international 20111001

Benefits of ticagrelor debated as antiplatelet class approaches generic market.

Managed care (Langhorne, Pa.) 20111001

Managing adverse effects and drug-drug interactions of antiplatelet agents.

Nature reviews. Cardiology 20110913

Ticagrelor (Brilinta)--better than clopidogrel (Plavix)?

The Medical letter on drugs and therapeutics 20110905

Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes.

European heart journal 20110901

Disposition and metabolism of ticagrelor, a novel P2Y12 receptor antagonist, in mice, rats, and marmosets.

Drug metabolism and disposition: the biological fate of chemicals 20110901

Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses.

Journal of thrombosis and haemostasis : JTH 20110901

Agreement between adjusted indirect comparison and simplified network meta-analyses on prasugrel and ticagrelor (Reply to Passaro et al. - Int J Cardiol 2011).

International journal of cardiology 20110901

P2 receptors and platelet function.

Purinergic signalling 20110901

P2Y₁₂ receptor inhibitors: integrating ticagrelor into the management of acute coronary syndrome.

The Annals of pharmacotherapy 20110901

Ticagrelor approved for acute coronary syndrome.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20110901

Evaluation of the effect of dapagliflozin on cardiac repolarization: a thorough QT/QTc study.

Diabetes therapy : research, treatment and education of diabetes and related disorders 20110901

Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes.

International journal of cardiology 20110804

Anti-platelet treatments in acute coronary syndrome: simplified network meta-analysis.

International journal of cardiology 20110804

Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.

Circulation 20110802

P2Y12 antagonists in acute coronary syndrome: in whom should they be started, and when?

Current cardiology reports 20110801

High platelet reactivity and clinical outcome - fact and fiction.

Thrombosis and haemostasis 20110801

Antithrombotic management for transient ischemic attack and ischemic stroke (other than atrial fibrillation).

Current atherosclerosis reports 20110801

Beyond aspirin and clopidogrel: is there a need for additional antiplatelet therapy in ACS?

Current cardiology reports 20110801

Effect of ticagrelor on the pharmacokinetics of ethinyl oestradiol and levonorgestrel in healthy volunteers.

Current medical research and opinion 20110801

Determination of unbound ticagrelor and its active metabolite (AR-C124910XX) in human plasma by equilibrium dialysis and LC-MS/MS.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110801

Prasugrel vs. ticagrelor in acute coronary syndromes: which one to choose?

Wiener klinische Wochenschrift 20110801

The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders.

Expert review of cardiovascular therapy 20110801

Impact of dyspnea on medical utilization and affiliated costs in patients with acute coronary syndrome.

Hospital practice (1995) 20110801

Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with mild hepatic impairment.

Journal of clinical pharmacology 20110701

Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials.

QJM : monthly journal of the Association of Physicians 20110701

The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies.

American heart journal 20110701

[Ticagrelor: a novel antiplatelet agent for patients with acute coronary syndrome].

Medizinische Monatsschrift fur Pharmazeuten 20110701

Non-interventional management of acute coronary syndromes.

BMJ (Clinical research ed.) 20110617

How to explain the reduced cardiovascular mortality in the ticagrelor arm of the PLATO trial?

International journal of cardiology 20110602

Novel antiplatelet agent ticagrelor in the management of acute coronary syndrome.

Journal of interventional cardiology 20110601

Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor.

Expert opinion on pharmacotherapy 20110601

Usefulness of a nanoparticle formulation to investigate some hemodynamic parameters of a poorly soluble compound.

Journal of pharmaceutical sciences 20110601

[Myocardial infarction: Role of new antiplatelet agents].

Presse medicale (Paris, France : 1983) 20110601

[Update on anti-platelet therapy].

Deutsche medizinische Wochenschrift (1946) 20110601

Ticagrelor for acute coronary syndrome?

Drug and therapeutics bulletin 20110601

Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysis.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20110601

The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy.

Journal of the American College of Cardiology 20110510

Ticagrelor: a review of its use in the management of acute coronary syndromes.

Drugs 20110507

[New approaches and indications for the analysis of platelet function in cardiology].

Hamostaseologie 20110502

Viewpoint: paradoxical excess mortality in the PLATO trial should be independently verified.